FDA approval of generic ARVs
2 April 2010. Related: Treatment access.
Since the last issue of HTB, the US Food and Drug Administration (FDA) has granted tentative approval for the following new generic ARV products.
| Drug and formulation | Manufacturer, Country | Approval date |
| Tenofovir DF, 300mg tabs | Hetero, India | 06 April 2010 |
| Nevirapine tablets for oral suspension, 50 mg, for children weighing >5 kg | Aurobindo, India | 24 February 2010 |
| Efavirenz cross-scored tablets, 200 mg (to be broken into two 100 mg or four 50 mg doses for paediatric dosing. | Strides Arcolab, India | 12 February 2010 |
Tentative Approval means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but because of existing patents and/or exclusivity rights, it cannot yet be marketed in the United States. Tentative approval does, however make the product eligible for consideration for purchase under the PEPFAR program for use outside the United States.
Effective patent dates are listed in the agencys publication titled Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book:
http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
comment
This brings the total of FDA approved generic drugs and formulations to 108 since the programme
started.
An updated list of generic tentative approvals is available on the FDA website:
http://www.fda.gov/oia/pepfar.htm
Source: FDA list serve:
<a
href=”http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm122951.htm”>http://www.fda.gov/ForConsumers/ByAudience/ForPat
ientAdvocates/HIVandAIDSActivities/ucm122951.htm